Related Experiment Video
Updated: Aug 14, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?
1Evanston Northwestern Healthcare Research Institute, Division of Microbiology, Department of Pathology and Laboratory Medicine, Northwestern University, Evanston, IL, USA. lancer@northwestern.edu
Background:
The rate of in vitro bacterial resistance to antimicrobial agents is escalating among pathogens that cause the most serious respiratory tract infections. Many reports published during the past few years suggest that this has direct clinical implications. In particular, resistance of Streptococcus pneumoniae to beta-lactam antibiotic therapy has assumed a prominent role in the evolution of guidelines for the initial treatment of respiratory tract infection.
Methods:
I conducted a critical review of the published medical literature.
Results:
There is only a single report of documented microbiologic failure of parenteral penicillin-class antibiotics in the treatment of pneumococcal pneumonia in patients with or without bacteremia, whereas there are numerous well-documented reports of treatment failure with quinolone-class (n > or = 21) and macrolide-class (n > or = 33) antibiotics in the treatment of pneumococcal pneumonia.
Conclusion:
The recommended optimal in-hospital therapy for community-acquired pneumonia should continue to be a beta-lactam antibiotic (penicillin, aminopenicillin, cefotaxime, or ceftriaxone) administered with a macrolide or a fluoroquinolone agent for adjunctive treatment of infection with potential atypical pathogens.
Insights
Beta-lactam antibiotics show superior efficacy in treating Streptococcus pneumoniae pneumonia compared to macrolides and fluoroquinolones. Current guidelines for community-acquired pneumonia should prioritize beta-lactams for optimal patient outcomes.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Increasing antimicrobial resistance in respiratory pathogens poses clinical challenges.
- Streptococcus pneumoniae resistance to beta-lactams impacts treatment guidelines for respiratory tract infections.
Purpose of the Study:
- To critically review the published medical literature on antimicrobial resistance in Streptococcus pneumoniae.
- To evaluate the clinical efficacy of different antibiotic classes for treating pneumococcal pneumonia.
Main Methods:
- A critical review of the existing medical literature was performed.
Main Results:
- Limited reports document microbiologic failure with parenteral penicillin-class antibiotics for pneumococcal pneumonia.
- Numerous reports indicate treatment failure with quinolone-class (n ≥ 21) and macrolide-class (n ≥ 33) antibiotics in pneumococcal pneumonia.
Conclusions:
- Beta-lactam antibiotics remain the recommended optimal in-hospital therapy for community-acquired pneumonia.
- Adjunctive macrolide or fluoroquinolone therapy is recommended for potential atypical pathogens.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Atypical Pneumonia
Development of Antibiotic Resistance
Production of Antibiotics
Clinical Significance of Antibiotic Resistance